Expertise in
3
conditions

Ollivier Legrand

Paris, FR 
Expertise in
3
conditions
Paris, FR 

Overview

Ollivier Legrand practices practicing medicine in Paris, France.

Legrand is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 3 clinical trials.

Locations

Paris, France
Other Locations
Saint Antoine, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Gemtuzumab ozogamicin
Study Phase: Phase 2/Phase 3
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
View 2 Less Clinical Trials

58 Total Publications

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
Journal: Leukemia & lymphoma
Published: July 26, 2026

Frequently Asked Questions about Ollivier Legrand

Is Ollivier Legrand a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Ollivier Legrand is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ollivier Legrand participate in research or clinical trials?

Yes. Ollivier Legrand has published 58 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Ollivier Legrand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Legrand's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile